Global Isothermal Nucleic Acid Amplification Technology/INAAT Market Size, Share, Forecast Report, 2020-2027

The global isothermal nucleic acid amplification technology (INAAT) market size is projected to reach USD 3.3 billion in 2024 from USD 1.9 billion in 2019, at a CAGR of 11.0% during the forecast period. Market growth is driven mainly by factors such as the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT. However, the extensive usage and reliance on PCR is a major factor restraining the growth of the INAAT market during the forecast period.
By product, assay, kits and reagents segment is expected to grow at the highest CAGR during the forecast period
Based on product, the market is segmented broadly into assay, kits and reagents and systems. The assay, kits and reagents segment is projected to grow at the highest CAGR during the forecast period because of increasing number of infectious disease diagnostic tests carried out; the increasing prevalence of infectious diseases; the continuous launch of newer, faster, and more reliable POC products; increasing approvals of CLIA-waived tests; accessibility to a wide range of reagents; repeated purchase of reagents; and the increasing use of reagents in therapeutics, basic research, and assay development.

By type, the transcription-mediated amplification segment is expected to witness the highest growth in the INAAT market during the forecast period.
Transcription mediated amplification segment is expected to show the highest growth in the forecast period. The large share of this segment is attributed to the growing reliance on POC diagnosis in hospitals and blood banks.

By application, the infectious disease diagnosis segment is expected to witness the highest growth in the INAAT market during the forecast period.
Infectious disease diagnosis is expected to show the highest growth in the forecast period owing to the increasing number of infectious disease diagnostic tests carried out and the rising prevalence of infectious diseases, among others.

By end-users, the hospital segment is growing at the highest CAGR during the forecast period.
The hospital segment is projected to register the highest growth rate during the forecast period because hospitals are equipped with fully automated INAAT instruments and offer test results quickly as compared to reference laboratories. Owing to these factors, the market for INAAT systems and consumables in hospitals is larger than the other end-user segments.
The INAAT market is divided into four major regions- Europe, North America, Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest share of the global market, closely followed by Europe. Factors such as the presence of a well-established healthcare system, access to technologically advanced diagnostics and blood screening techniques, recommendations for blood screening, high and growing burden of infectious diseases, rising number of genome-based drug development activities, and the availability of R&D funding for genomics research are the major factors that are expected to drive the growth of the North American market during the forecast period.

Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Factors such as the sustained economic growth in several Asia Pacific countries, the rising disposable income, healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostic technologies (including INAAT) for research and clinical applications, high infectious disease burden, availability of low-cost POC INAAT assays, and growing awareness among physicians and healthcare professionals about the benefits of gene-based disease diagnosis and treatment in Asia Pacific countries are expected to support market growth in this region during the forecast period.

Key Market Players
The major companies in the INAAT market include Grifols S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and Meridian Bioscience (US).

Based on the product:

• Assay, Kits and Reagents
• Systems

Based on the type:

• TMA
• LAMP
• SDA
• HDA
• NASBA
• Other Technologies (recombinase polymerase amplification (RPA), single-primer isothermal amplification (SPIA), signal-mediated amplification of RNA technology (SMART), rolling circle amplification (RCA), cross-priming amplification (CPA), circular helicase-dependent amplification (cHDA), nicking enzyme amplification reaction (NEAR), and multiple displacement amplification (MDA)

Based on the application:

• Infectious Disease Diagnosis
  • Hepatitis
  • CT/NG
  • HIV
  • Influenza
  • Other Infectious Disease (hospital acquired infections (HAIs), tuberculosis, HPV, streptococcus, malaria, Zika, dengue, West Nile virus, respiratory syncytial virus, pneumonia, trichomonas vaginalis, genital mycoplasma, herpes simplex virus, pertussis, Bordetella, norovirus, and rotavirus)
• Blood Screening
• Other Applications (cancer diagnosis, cancer research, and laboratory research, which encompass cDNA preparation, whole-genome amplification (WGA), single-nucleotide polymorphism (SNP), and mutation analysis)

Based on end user:

• Hospital
• Reference Laboratories
• Academic and Research Institutes
• Other end user (physicians’ offices and clinics, blood banks, donor banks, community clinic laboratories, and IVD manufacturers. Physicians’ offices and clinics, blood banks, donor banks, and community clinic laboratories)

Based on the region:

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • RoE
• Asia Pacific
• RoW